Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RTN-001 in Uncontrolled Hypertension
NCT07142356Phase 2Recruiting
- Sponsor
- Retension Pharmaceuticals
- Start
- Oct 2025
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of RTN-001 in hypertension (HTN) (4 arms), sponsored by Retension Pharmaceuticals. Primary endpoint: Systolic Blood Pressure at 4 weeks. Started Oct 2025; status: recruiting.
02
Drugs
RTN-001
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT07142356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07142356.